Vilazodon

Vilazodon
(IUPAC) ime
	5-(4-[4-(5-cijano-1H-indol-3-il)butil]piperazin-1-il)benzofuran-2-karboksamid
Klinički podaci
Robne marke	Viibryd
AHFS/Drugs.com	Potrošačka informacije o leku
MedlinePlus	a611020
Identifikatori
CAS broj	163521-12-8
ATC kod	N06AX24
PubChem	6918313
ChemSpider	5293518
UNII	S239O2OOV3
KEGG	D09698
ChEMBL	CHEMBL439849
Hemijski podaci
Formula	C26H27N5O2
Mol. masa	441,524 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) ; Key: SGEGOXDYSFKCPT-UHFFFAOYSA-N
Farmakokinetički podaci
Poluvreme eliminacije	20-24 sata
Farmakoinformacioni podaci
Licenca	US FDA:link
Trudnoća	C(US)
Pravni status	℞-only (SAD)
Način primene	Oralno

Vilazodon (Viibryd) je serotinergički antidepresiv koji je razvijen za tretman kliničke depresije.^[6] FDA je odobrila upotrebu vilazodona 2011.^[7]^[8]^[9]

Farmakologija

Vilazodon deluje kao inhibitor preuzimanja serotonina (IC₅₀ = 0.5 nM) i parcijalni agonist 5-HT_1A receptora (IC₅₀ = 0.2 nM; IA = ~60-70%).^[10]^[11] On ima neznatan afinitet za druge serotoninske receptore kao što je 5-HT_1D, 5-HT_2A, i 5-HT_2C.^[10]^[11]

References

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ de Paulis T (March 2007). „Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression”. IDrugs : the Investigational Drugs Journal 10 (3): 193–201. PMID 17351874.
↑ „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011..
↑ „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011..
↑ „Clinical Data, Inc. - Clinical Data, Inc. Submits New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder”. Arhivirano iz originala na datum 2011-08-18.
↑ ^10,0 ^10,1 Page ME, Cryan JF, Sullivan A, et al. (September 2002). „Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist”]. The Journal of Pharmacology and Experimental Therapeutics 302 (3): 1220–7. DOI:10.1124/jpet.102.034280. PMID 12183683.
↑ ^11,0 ^11,1 Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). „Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone”. European Journal of Pharmacology 510 (1–2): 49–57. DOI:10.1016/j.ejphar.2005.01.018. PMID 15740724.

Povezano

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid17351874-6] Paulis T (March 2007). „Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression”. IDrugs : the Investigational Drugs Journal 10 (3): 193–201. PMID 17351874.

[approval-7] „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011..

[FDA_approves_Clinical_Data_Inc's_antidepressant-8] „FDA approves Clinical Data Inc's antidepressant”. Reuters. 22. 1. 2011..

[urlClinical_Data,_Inc._-_Clinical_Data,_Inc._Submits_New_Drug_Application_for_Vilazodone_for_the_Treatment_of_Major_Depressive_Disorder-9] „Clinical Data, Inc. - Clinical Data, Inc. Submits New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder”. Arhivirano iz originala na datum 2011-08-18.

[pmid12183683-10] 10,0 ^10,1 Page ME, Cryan JF, Sullivan A, et al. (September 2002). „Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist”]. The Journal of Pharmacology and Experimental Therapeutics 302 (3): 1220–7. DOI:10.1124/jpet.102.034280. PMID 12183683.

[pmid15740724-11] 11,0 ^11,1 Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). „Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone”. European Journal of Pharmacology 510 (1–2): 49–57. DOI:10.1016/j.ejphar.2005.01.018. PMID 15740724.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]